BIONDVAX PHARMACEUTICALS-ADR (BVXV) Fundamental Analysis & Valuation

NASDAQ:BVXV • US09073Q2049

1.36 USD
+0.05 (+3.82%)
At close: Sep 6, 2023
1.38 USD
+0.02 (+1.47%)
After Hours: 9/6/2023, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BVXV fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BVXV. BVXV was compared to 193 industry peers in the Pharmaceuticals industry. BVXV has a bad profitability rating. Also its financial health evaluation is rather negative. BVXV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. BVXV Profitability Analysis

1.1 Basic Checks

  • In the past year BVXV has reported negative net income.
BVXV Yearly Net Income VS EBIT VS OCF VS FCFBVXV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • BVXV has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BVXV Yearly ROA, ROE, ROICBVXV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 100 -100 200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BVXV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BVXV Yearly Profit, Operating, Gross MarginsBVXV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. BVXV Health Analysis

2.1 Basic Checks

  • BVXV has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for BVXV is higher compared to a year ago.
BVXV Yearly Shares OutstandingBVXV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500K 1M 1.5M 2M 2.5M
BVXV Yearly Total Debt VS Total AssetsBVXV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • Based on the Altman-Z score of -7.98, we must say that BVXV is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -7.98, BVXV is doing worse than 72.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.98
ROIC/WACCN/A
WACCN/A
BVXV Yearly LT Debt VS Equity VS FCFBVXV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 4.28 indicates that BVXV has no problem at all paying its short term obligations.
  • The Current ratio of BVXV (4.28) is comparable to the rest of the industry.
  • A Quick Ratio of 4.28 indicates that BVXV has no problem at all paying its short term obligations.
  • BVXV's Quick ratio of 4.28 is in line compared to the rest of the industry. BVXV outperforms 59.13% of its industry peers.
Industry RankSector Rank
Current Ratio 4.28
Quick Ratio 4.28
BVXV Yearly Current Assets VS Current LiabilitesBVXV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. BVXV Growth Analysis

3.1 Past

  • The earnings per share for BVXV have decreased strongly by -93.48% in the last year.
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 24.98% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BVXV Yearly EPS VS EstimatesBVXV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. BVXV Valuation Analysis

4.1 Price/Earnings Ratio

  • BVXV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BVXV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BVXV Price Earnings VS Forward Price EarningsBVXV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BVXV Per share dataBVXV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BVXV's earnings are expected to grow with 24.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.02%
EPS Next 3Y24.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BVXV Dividend Analysis

5.1 Amount

  • BVXV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

BVXV Fundamentals: All Metrics, Ratios and Statistics

BIONDVAX PHARMACEUTICALS-ADR

NASDAQ:BVXV (9/6/2023, 8:00:01 PM)

After market: 1.38 +0.02 (+1.47%)

1.36

+0.05 (+3.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-11
Earnings (Next)N/A
Inst Owners6.93%
Inst Owner Change0%
Ins Owners18.86%
Ins Owner Change0%
Market Cap4.97M
Revenue(TTM)N/A
Net Income(TTM)-10.92M
Analysts82.86
Price Target39.78 (2825%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-46.39%
Min EPS beat(2)-46.39%
Max EPS beat(2)-46.39%
EPS beat(4)2
Avg EPS beat(4)48.25%
Min EPS beat(4)-46.39%
Max EPS beat(4)109.8%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.86
EYN/A
EPS(NY)-2.6
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-1.32
TBVpS-1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.28
Quick Ratio 4.28
Altman-Z -7.98
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)239.78%
Cap/Depr(5y)2174.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.5%
EPS Next Y99.29%
EPS Next 2Y18.02%
EPS Next 3Y24.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-229.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y91.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y91.08%
OCF growth 3YN/A
OCF growth 5YN/A

BIONDVAX PHARMACEUTICALS-ADR / BVXV FAQ

What is the ChartMill fundamental rating of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

ChartMill assigns a fundamental rating of 1 / 10 to BVXV.


What is the valuation status of BIONDVAX PHARMACEUTICALS-ADR (BVXV) stock?

ChartMill assigns a valuation rating of 1 / 10 to BIONDVAX PHARMACEUTICALS-ADR (BVXV). This can be considered as Overvalued.


Can you provide the profitability details for BIONDVAX PHARMACEUTICALS-ADR?

BIONDVAX PHARMACEUTICALS-ADR (BVXV) has a profitability rating of 0 / 10.


What is the earnings growth outlook for BIONDVAX PHARMACEUTICALS-ADR?

The Earnings per Share (EPS) of BIONDVAX PHARMACEUTICALS-ADR (BVXV) is expected to grow by 99.29% in the next year.